Savarese G, et al. - As renin-angiotensin system inhibitors (RASi) improve morbidity and mortality in heart failure with reduced ejection fraction (HFrEF), researchers investigated their effect in patients with HFrEF aged > 80 years. They analyzed patients with ejection fraction < 40% and age > 80 years from the Swedish Heart Failure Registry. They found that patients with HFrEF aged >80 years receive RASi relatively less frequently than younger patients, despite similar association with reduced morbidity and mortality and no apparent association with risk of syncope-related hospitalization.